FDA, Industry To Broach Whether 'Abuse Deterrent' Properly Describes ADFs

May 14, 2018
FDA and producers of so-called abuse-deterrent formulations of opioids -- dubbed ADFs -- are expected to discuss at an upcoming meeting whether the words “abuse-deterrent” should be changed or better described when associated with such products, coming as the agency also faces pressure from Congress to broach the issue. Many public health and consumer advocates have argued doctors and patients often mistake the abuse-deterrent designation to mean ADF opioids are abuse-proof. The upcoming meeting between ADF representatives and FDA offers...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on the coming Democrat-controlled House of Representatives, drug pricing reforms, Medicaid policy, FDA news and much more.